Efficacy of Prednisolone on ICSI outcomes in a group of women with recurrent implantation failure

Evaluation of the effect of prednisolone on ICSI outcomes in women with immunological recurrent implantation failure

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016091618662N2

Enrollment

220

Registered

2016-09-19

Start date

2016-09-24

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: unovulation female infertility. Condition 2: tubal female inferility. Condition 3: male factor female infertility. Condition 4: unspecified female infertility. Condition 5: complication of artificial fertilization. Female infertility associated with anovulation Female infertility of tubal origin Female infertility associated with male factors Female infertility, unspecified Complication associated with artificial fertilization, unspecified

Interventions

Intervention 1: placebo of prednisolone about 1.5 months. Intervention 2: prednisolone 10 mg daily about 1.5 months.

Placebo

Treatment - Drugs

placebo of prednisolone about 1.5 months

prednisolone 10 mg daily about 1.5 months

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1- At least 2 unsuccessful IVF/ICSI cycles 2- Grade A or AB of transferred embryos in previous cycles and at least 6 embryos transferred 3- Age10 milion counts, >3% normal morphology Exclusion Criteria: 1- Utilization of donation systems 2- Uncontrolled diseases such as Diabetes, HTN, Lupus, Renal failures,... 3- Abnormal Katyotype 4- Anatomical abnormalities( congenital, submucosal myoma, Asherman syn,...) 5- Endometriosis grade 3, 4 6- Women who had Endometrial scratch in the same cycle

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
ICSI Outcome(chemical pregnancy). Timepoint: two weeks afert embryo transfer. Method of measurement: serum Beta HCG.;Clinical pregnancy. Timepoint: three weeks after embryo transfer. Method of measurement: transvaginal ultrasound.	—

Secondary

Measure	Time frame
Oocyte quality. Timepoint: on the oocyte collection day. Method of measurement: morphologic assesment with microscope.;Embryo quality. Timepoint: 2 or 3 days after oocyte collection. Method of measurement: morphologic assesment with microscope.;Fertilization rate. Timepoint: 2 or 3 days after oocyte collection. Method of measurement: (embros number/injected oocytes numbers) * 100.;Prednisolone complications. Timepoint: any time of trial. Method of measurement: history and lab tests.	—

Measure

Time frame

Oocyte quality. Timepoint: on the oocyte collection day. Method of measurement: morphologic assesment with microscope.;Embryo quality. Timepoint: 2 or 3 days after oocyte collection. Method of measurement: morphologic assesment with microscope.;Fertilization rate. Timepoint: 2 or 3 days after oocyte collection. Method of measurement: (embros number/injected oocytes numbers) * 100.;Prednisolone complications. Timepoint: any time of trial. Method of measurement: history and lab tests.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farnaz Fatemi

Avicenna Infertility Clinic

Dr.farnazfatemi@Gmail.com+98 21 23519

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026